Search / Trial NCT00002265

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

Launched by HOFFMANN-LA ROCHE · Aug 30, 2001

Apply for Trial

Trial Information

Current as of January 02, 2025

Completed

Keywords

Zalcitabine Drug Evaluation Acquired Immunodeficiency Syndrome Aids Related Complex Zidovudine

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • • Inclusion Criteria
  • Concurrent Medication:
  • Recommended:
  • • Prophylactic aerosolized pentamidine.
  • * Allowed for maintenance after recovering from infection for which initially prescribed:
  • • Pyrimethamine.
  • • Sulfadiazine.
  • • Amphotericin.
  • • Fluconazole.
  • • Ketoconazole (= or \< 400 mg/day).
  • • Acyclovir ( = or \< 1000 mg/day).
  • • Ganciclovir.
  • • Medications for tuberculosis or Mycobacterium avium infection.
  • * Allowed:
  • • Erythropoietin.
  • • Megace.
  • • Trimethoprim/sulfamethoxazole \< or = 20 mg/kg/day.
  • • Nystatin.
  • • Low dose acetaminophen or non-steroidal anti-inflammatory agents ( = or \< 3 g/day).
  • • Medications on which patient has been stable for 14 days prior to study entry.
  • * Allowed if no evidence of peripheral neuropathy at study entry:
  • • Isoniazid (must be receiving pyridoxine = or \> 50 mg/day concomitantly).
  • • Phenytoin, if stable for = or \> 3 months.
  • • Metronidazole with a study medication interruption and pre and post testing for peripheral neuropathy. Any signs of this and the patient will not be restarted on study medication.
  • • REFER TO NOTE OF CAUTION IN PROTOCOL SUMMARY.
  • Patients must have the following:
  • • Previously enrolled in NIAID ACTG 114 or NIAID ACTG 119.
  • • Experienced = or \> grade 3 zidovudine (AZT) related toxicity while enrolled in the assigned protocol and followed the procedures for the study drug dose reduction, interruption, rechallenge and permanent discontinuation as per NIAID ACTG 114 or NIAID ACTG 119.
  • * NOTE:
  • • After permanent study drug discontinuation from NIAID ACTG 114 the drug code may be broken ONLY after discussion with Hoffmann-La Roche regarding toxicity management and probable relationship to AZT. Although NIAID ACTG 119 is an open-label study, investigators should also contact Hoffmann-La Roche prior to entering any patient into this protocol.
  • • Toxicities must be "probably" AZT related (as determined by the investigator and following discussion by sponsor) for patients to be eligible for inclusion into this protocol.
  • • Toxicities must be resolved to = or \< grade 2 within 45 days of discontinuation from AZT in NIAID ACTG 114 or NIAID ACTG 119.
  • • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • • An active AIDS defining opportunistic infection or other active intercurrent illnesses if their ongoing treatment requires the use of excluded medications (see Exclusion - Concurrent Medications).
  • • Baseline fever \> 38.5 C if caused by an occult opportunistic infection or neoplasm and requiring continuous treatment with excluded medications. If the evaluation for infection is unrevealing, the patient may be entered after the evaluation is completed but while mycobacterial cultures are still pending. Patients with a history of unexplained fever \> 38.5 C should be evaluated as above and/or be afebrile (T \< 38.0 C) for 2 weeks prior to study entry.
  • • Severe AIDS dementia complex as defined by a score of \< 23 on the Mini-Mental State Exam at the time of discontinuation from NIAID ACTG 114 or NIAID ACTG 119.
  • * Any history of peripheral neuropathy or moderate to severe peripheral neuropathy as defined below:
  • • A score of = or \> 4 in any one category or a score of = or \> 2 in two categories of the peripheral neuropathy segment of the Signs and Symptoms Questionnaire.
  • * Accompanied by:
  • • Results on the Standardized Neurological exam indicative of a moderate abnormality, particularly impaired sensation of sharp pain, light touch or vibration in lower extremities, distal extremity weakness or distal extremity hyporeflexia.
  • • Significant cardiac disease, defined as history of ventricular arrhythmias requiring medication, prior myocardial infarct or history of angina or ischemia changes on EKG.
  • • Significant liver disease, as defined by transaminases \> 5 x upper limit of normal or a history of cirrhosis or ascites.
  • • Significant renal disease as defined by an estimated creatinine clearance \< 50 ml/min.
  • Concurrent Medication:
  • Excluded:
  • • Other antiretroviral agents.
  • • Biologic modifiers.
  • • Corticosteroids.
  • * Other experimental agents including:
  • • Foscarnet.
  • • Ribavirin.
  • • ddI.
  • * Drugs that could cause peripheral neuropathy including:
  • • Hydralazine.
  • • Nitrofurantoin.
  • • Vincristine.
  • • Cisplatin.
  • • Dapsone.
  • • Disulfiram.
  • • Diethyldithiocarbamate.
  • Patients with the following are excluded:
  • • An active AIDS defining opportunistic infection or other active intercurrent illnesses if their ongoing treatment requires the use of excluded medications (see Exclusion - Concurrent Medications). Such patients will be allowed into the study if they have completed therapy with an excluded concomitant medication and are stable for 14 days. Had to discontinue study medication in NIAID ACTG 114 or NIAID ACTG 119 because of an opportunistic infection or intercurrent illness which required continuous treatment with medications allowed for concomitant administration in NIAID ACTG 114 or ACTG 119. Symptoms and conditions defined in patient Exclusion - Co-Existing Condition. Active substance or alcohol abuse. Unwillingness or deemed unable to sign informed consent.
  • Prior Treatment:
  • Excluded within 30 days of study entry:
  • • Radiation therapy.
  • • Active substance or alcohol abuse.

About Hoffmann La Roche

Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.

Locations

Atlanta, Georgia, United States

Detroit, Michigan, United States

Miami, Florida, United States

San Francisco, California, United States

San Francisco, California, United States

Philadelphia, Pennsylvania, United States

Fort Lauderdale, Florida, United States

Fort Myers, Florida, United States

Dallas, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials